Device Trial Radar · NCT02461576
Clinical Evaluation of the Xpert® HIV-1 VL
Last checked: Nov 20, 2026Latest source record: Feb 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
966
Actual
Start
Jul 2015
Primary completion
Feb 24, 2017
Study completion Feb 24, 2017
Sponsor
- Lead sponsor
- CepheidNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 3, 2015
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Compare the clinical performance of the Xpert® HIV-1 VL to another FDA approved HIV-1 RNA quantitative assay using frozen and fresh specimens from known HIV-1 positive individuals.
Conditions
- Human Immunodeficiency Virus
Interventions
Xpert HIV-1 VL AssayDevice
in vitro diagnostic test to quantify HIV-1 RNA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quantification of HIV-1 RNA in copies/mL in known HIV-1 positive subjectsTime frame: 1 day (A single time point)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.